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This fall, as we welcome new PGY1 
residents and a host of new faculty 
members, there is great excitement here  
in the Department of Surgery.
On the clinical front, we have gained 
additional work at the Methodist Hospital, 
have grown the Heart Transplant and 
Advanced Heart Failure Program, have seen 
an upswing in liver transplants, and are now 
the busiest hospital by surgical volume for 
pancreas resections in the tri-state area!  
On the quality front, Dr. Herbert Cohn and 
Randi Altmark, RN, BSN, CNOR have done 
a tremendous job with the National Surgical 
Quality Improvement Program. Using those 
data we have organized the Surgical Care 
Committee and new Surgical Care Bundle 
and are driving changes in practice, and 
hopefully, better outcomes.
On the research front, our grant submissions 
have doubled in the last three years. 
Total grant awards for the last fiscal year 
approached $2 million. We have completed 
a large prospective randomized trial looking 
at pancreaticojejunostomy following the 
Whipple procedure, and have clinical trials 
open in the Divisions of Vascular, Cardiac, 
Transplant and General Surgery. 
On the education front, Dr. Karen Chojnacki 
has done a great job retooling our surgical 
curriculum with the help of Drs. Niels 
Martin and Vincent Armenti, and the  
Chief Residents.
Finally, we thank Lara Allan Goldstein for her 
work in greatly increasing the department’s 
development dollars – most recently 
accepting a generous gift from the Nicoletti 
family to support an endowed professorship 
in transplant surgery.
The Jefferson Pancreas Tumor Registry 
(Jeff PTR) has been approved by the 
Institutional Review Board of Thomas 
Jefferson University Hospital and is 
designed to help determine the links 
between familial genetic variations, 
environmental and occupational 
influences, and the development of 
pancreatic cancer
According to Principal Investigator, 
Dr. Charles J. Yeo, “The purpose of the 
Jeff PTR is to determine whether 
pancreas cancer occurs more frequently 
in families with a history of the disease, 
and to determine the environmental and 
occupational risk factors to which 
pancreas cancer patients have been 
exposed.” Participants will complete a 
detailed questionnaire and may be asked 
to submit a blood sample and/or cheek 
swab. The questionnaire is designed to 
elicit the family health history of a 
patient with pancreas cancer or a non-
affected family member, and to 
document exposure to occupational and 
environmental factors, such as residential 
radon, asbestos, and second-hand 
tobacco smoke. The Jeff PTR is a 
longitudinal study in which participants 
may engage in long-term follow-up and 
receive information regarding scientific 
and epidemiological breakthroughs in 
pancreas cancer. 
Research has shown that certain rare 
genetic conditions are associated with an 
increased risk of pancreatic cancer, 
including familial breast-ovarian cancer, 
familial melanoma, familial colon cancer, 
hereditary pancreatitis, and Peutz-Jegher’s 
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Meet Our  
Surgical Interns
Jefferson surgeons are 
currently assisted by 
an exceptional group of 
categorical interns, half of 
them Jefferson Medical 
College graduates. These 
doctors, who recently 
matched with Jefferson, 
started on June 20, 2008 (l to r):
Danielle Pineda, MD, Jefferson Medical 
College; Richard Burkhart, MD, Boston 
University School of Medicine;  
Aleksandra Policha, MD, SUNY/Syracuse; 
Daniel Relles, MD, Jefferson Medical College; 
Christina Khan, MD, PhD, University of Illinois; 
Genetic Counselor Sarah Charles, MS, CGC of the Jefferson Kimmel Cancer Center Network 
(JKCCN) educates families about their risk of developing an inherited disorder.
Overview Clinical Integration
Please Welcome
The goal is to diagnose 
pancreatic cancer early when 
it is easier to treat.
and Jason Walls, MD, Jefferson  
Medical College
We are also pleased to welcome back 
two additional Jefferson Medical College 
graduates, Carrie Houssock, MD, and Jordan 
Goldhammer, MD, as preliminary interns in 
General Surgery. 
syndrome. Genetic Counselor Sarah 
Charles, MS, CGC of the Jefferson 
Kimmel Cancer Center Network 
(JKCCN) educates families about their 
risk of developing an inherited disorder. 
Ms. Charles explains, “We haven’t yet 
identified a causative gene to allow 
predictive testing for pancreatic cancer. 
But, for patients with a strong family 
history of pancreatic cancer, we can offer 
risk assessments and possibly surveillance 
with endoscopic ultrasound.”
Such high risk patients may be 
referred to Jefferson gastroenterologists 
such as Thomas Kowalski, MD and 
David Loren, MD to discuss the pros and 
cons of invasive surveillence. The goal is 
to diagnose pancreatic cancer early when 
it is easier to treat. For persons who do 
develop pancreatic cancer, Jefferson 
physicians may use the results of genetic 
testing to select the most effective 
therapy. Targeted therapy for pancreas 
cancer is becoming a reality in part due 
to recent discoveries made in the 
laboratory of Jonathan Brody, PhD, 
Assistant Professor of Surgery, where 
molecular studies have clearly indicated 
survival advantages with the use of 
targeted chemotherapy treatment. 
For more information about the Jefferson  
Pancreas Tumor Registry please visit  
www.jeffersonhospital.org/pancreasregistry
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